CEL-SCI Corp (CEL-SCI) is a biotechnology company involved in the research and development of immunotherapy products for the treatment of cancer, autoimmune, and infectious diseases. The company focuses on cancer immunotherapy, particularly with its lead investigational therapy, Multikine, which is being developed for the treatment of head and neck cancer. CEL-SCI also focuses on developing its LEAPS technology for potential treatments of rheumatoid arthritis and other diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

CEL-SCI is engaged in research and development initiatives focused on improving cancer treatment and other diseases by leveraging the immune system. The company is developing Multikine, an investigational immunotherapy for head and neck cancers. Multikine has been granted orphan drug designation for this disease. It is also working on a peptide-based immunotherapy, CEL-4000, as a vaccine for rheumatoid arthritis using its LEAPS technology platform. As of September 2024, CEL-SCI announced results from its Phase III study for Multikine and is in the process of completing pre-IND studies for CEL-4000. Additionally, the company has entered into an agreement with Ergomed Clinical Research Inc for clinical development services related to an upcoming confirmatory registration study. In FY2024, the company spent US$18.2 million on R&D, which decreased 19.2% YoY.